ArticleACS medicinal chemistry letters2017
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Modeling the public health impact of voxelotor in the management of sickle cell disease in France.PloS one · 2023Pooled it
- Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients.Clinical pharmacology and therapeutics · 2026Trial
- One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.Blood advances · 2023Trial
- Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.British journal of clinical pharmacology · 2019Trial
- Trial
- A second-generation "hypoxia in a pill" rescues neurodegenerative phenotypes across distinct mouse models.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- Photochemical Deracemization of Aza-1-isoindolinones: Critical Influence of Catalyst Substitution and the Nature of Its Resting State.Journal of the American Chemical Society · 2026Article
- Characterization of the Second-Generation Covalent Fragment Library (CovLib Gen2): Thiol Reactivity Profiling and p53-Y220C Rescue.Drug design, development and therapy · 2026Article
- Potent Antisickling Furaldehyde Analogs for Acute Sickle Cell Therapy: Enhanced Efficacy and Intravenous Formulation Potential.ChemMedChem · 2025Article
- Discovery of Osivelotor (GBT021601): A Potent, Next-Generation Sickle Hemoglobin Polymerization Inhibitor.ACS medicinal chemistry letters · 2025Article
- Structure-based rational design of covalent probes.Communications chemistry · 2025Review
- Oxygen dissociation curve inflection point during incremental exercise: a trigger for the Bohr effect.Pflugers Archiv : European journal of physiology · 2025Article
- Michael Acceptor Compounds as Hemoglobin Oxygen Affinity Modulators for Reversing Sickling of Red Blood Cells.Pharmaceuticals (Basel, Switzerland) · 2025Article
- HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity.Cell · 2025Article
- Sticking together: Polymerization of sickle hemoglobin drives the multiscale pathophysiology of sickle cell disease.Biophysics reviews · 2025Review
- Promising role of voxelotor in managing sickle cell disease in children: a narrative review.Clinical and experimental pediatrics · 2025Article
- A review on disease modifying pharmacologic therapies for sickle cell disease.Annals of hematology · 2025Review
- Hemoglobin Variants as Targets for Stabilizing Drugs.Molecules (Basel, Switzerland) · 2025Review
- The antisickling agent, 5-hydroxymethyl-2-furfural: Other potential pharmacological applications.Medicinal research reviews · 2024Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Brian MetcalfGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Chihyuan ChuangCytokinetics, Inc. , South San Francisco, California 94080, United States.
Kobina DufuGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Mira P PatelGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Abel Silva-GarciaGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Carl JohnsonGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Qing LuCytokinetics, Inc. , South San Francisco, California 94080, United States.
James R PartridgeGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Larysa PatskovskaAlbert Einstein College of Medicine , Bronx, New York 10461, United States.
Yury PatskovskyAlbert Einstein College of Medicine , Bronx, New York 10461, United States.
Steven C AlmoAlbert Einstein College of Medicine , Bronx, New York 10461, United States.
Matthew P JacobsonDepartment of Pharmaceutical Chemistry, University of California , San Francisco, California 94158, United States.
Lan HuaDepartment of Pharmaceutical Chemistry, University of California , San Francisco, California 94158, United States.
Qing XuGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Stephen L GwaltneyGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Calvin YeeGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Jason HarrisGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Bradley P MorganCytokinetics, Inc. , South San Francisco, California 94080, United States.
Joyce JamesCytokinetics, Inc. , South San Francisco, California 94080, United States.
Donghong XuCytokinetics, Inc. , South San Francisco, California 94080, United States.
Athiwat HutchaleelahaGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Kumar PaulvannanTandem Sciences, Inc. , Menlo Park, California 94025, United States.
Donna OksenbergGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Zhe LiGlobal Blood Therapeutics, Inc. , South San Francisco, California 94080, United States.
Funding
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STROUD, ROBERT M · 2007 to 2018
$48.8MYeast ExpressionP50GM073210 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STROUD, ROBERT M · 2004 to 2013
$21.5MProject 6 (Holton)U54GM094625 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MINOR, DANIEL L · 2010 to 2014
$8.0MMINOS (Macromolecular Insights on Nucleic acids Optimized by Scattering)R01GM105404 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI TAINER, JOHN A. · 2012 to 2015
$2.1MNIGMS NIH HHS P50 GM073210NIGMS NIH HHS P50 GM082250NIGMS NIH HHS R01 GM105404NIGMS NIH HHS U54 GM094625
Abstract
We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (
Indexed as
aldehydeallosteric modulatoroxygen affinityred blood cell partitioningSchiff-base formationSickle cell diseasesickle cell hemoglobin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.